Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $161.14 Average Price Target from Analysts
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-two brokerages that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating on the company. The average 12 month […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-two brokerages that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating on the company. The average 12 month […]
